Clavesin-1 (CLVS1)

Clavesin-1 (CLVS1) is a vesicle trafficking protein involved in regulation of late endosome and lysosome morphology, with roles in clathrin-mediated endocytosis and phosphatidylinositol-3,5-bisphosphate binding[1][3][6]. While it is highly expressed in neurons, recent studies have established a critical function in kidney podocytes, where it contributes to the maintenance of the glomerular filtration barrier through endocytic regulation and oxidative stress protection[1]. Loss-of-function mutations in CLVS1—such as the rare autosomal recessive p.H310Y variant—are associated with familial, steroid-sensitive nephrotic syndrome, presumably by compromising clathrin-mediated endocytosis and increasing susceptibility to apoptosis via elevated reactive oxygen species[1]. Corticosteroids and antioxidants can rescue some of these functional defects, illustrating why corticosteroid responsiveness is a hallmark of this genetic nephrotic syndrome. There is no evidence that CLVS1 is a typical drug target (receptor, enzyme, transporter) or that there are drugs designed specifically to modulate this protein's function in clinical practice[1][3][6].

Other names

Cellular retinaldehyde-binding protein-likeRetinaldehyde-binding protein 1-like 1CRALBPLRLBP1L1MGC34646C6orf212Lclathrin vesicle-associated Sec14 protein 1

Corticosteroids: Restore podocyte viability and endocytic function via anti-apoptotic and endocytosis modulation pathways in CLVS1-deficient cells. ROS inhibitors: Reduce oxidative stress-mediated apoptosis caused by defective CLVS1.